TRAV13-2 and Schwartz-Jampel syndrome: Significant expansion of CD4+ cytotoxic T-lymphocytes and CD4+ TRAV13-2+ T cell in SjS, upregulated type I and II IFN signaling, and increased expression of ISGs (IFITM3, IFITM2, IFITM1, and XAF1).